In addition, we studied sACE2 levels in treatment-naïve and chemotherapy-, targeted-therapy-, or immunotherapy-treated NSCLC patients and malignant pleural mesothelioma patients to study if SOC therapies affect ACE2 levels in these patients. This evidence concerns the gene ACE2 and non-small cell lung carcinoma.